Trevi Therapeutics (TRVI) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TRVI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Trevi Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.53 |
| 52 Week High | US$11.11 |
| 52 Week Low | US$2.36 |
| Beta | 0.74 |
| 1 Month Change | 20.07% |
| 3 Month Change | 41.91% |
| 1 Year Change | 241.88% |
| 3 Year Change | 426.50% |
| 5 Year Change | 209.71% |
| Change since IPO | 33.46% |
Recent News & Updates
Recent updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Apr 02
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Sep 27We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Trevi adds 19% on full data set from mid-stage cough study
Sep 19Trevi Therapeutics: Moving Forward
Sep 11Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Shareholder Returns
| TRVI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.1% | 0.04% | 2.1% |
| 1Y | 241.9% | -4.7% | 18.7% |
Return vs Industry: TRVI exceeded the US Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: TRVI exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRVI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TRVI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 33 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.
Trevi Therapeutics, Inc. Fundamentals Summary
| TRVI fundamental statistics | |
|---|---|
| Market cap | US$1.28b |
| Earnings (TTM) | -US$47.30m |
| Revenue (TTM) | n/a |
Is TRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRVI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.30m |
| Earnings | -US$47.30m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRVI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 14:09 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trevi Therapeutics, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Joshua Schimmer | Cantor Fitzgerald & Co. |